Evidence map›Paper›PMID 25024437›Full record

ArticleThe EMBO journal2014

Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation.

Laura A Díaz-Martínez, Zemfira N Karamysheva, Ross Warrington, Bing Li, Shuguang Wei, Xian-Jin Xie, Michael G Roth, Hongtao Yu

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Multifaceted Regulation of Mitochondrial Dynamics During Mitosis.Frontiers in cell and developmental biology · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Cell-Cycle Cross Talk with Caspases and Their Substrates.Cold Spring Harbor perspectives in biology · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Laura A Díaz-MartínezDepartment of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Zemfira N KaramyshevaDepartment of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ross WarringtonDepartment of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bing LiDepartment of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shuguang WeiDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xian-Jin XieCenter for Biostatistics and Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Michael G RothDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hongtao YuDepartment of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA hongtao.yu@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USHoward Hughes Medical Institute · US

Funding

Characterization of the biological activities of novel epigenetic modulatorsR01CA125269 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MARTINEZ, ELISABETH D · 2010 to 2014
$1.8M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA125269NCI NIH HHS R01CA125269
6 · The paper itself

Abstract

The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, spindle checkpoint-dependent mitotic arrest in cancer cells. These cells then either undergo apoptosis triggered by the intrinsic mitochondrial pathway or exit mitosis without proper cell division in an adaptation pathway. Using a genome-wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify components of the mitotic apoptosis and adaptation pathways. We show that the Mad2 inhibitor p31(comet) actively promotes mitotic adaptation through cyclin B1 degradation and has a minor separate function in suppressing apoptosis. Conversely, the pro-apoptotic Bcl2 family member, Noxa, is a critical initiator of mitotic cell death. Unexpectedly, the upstream components of the mitochondrial apoptosis pathway and the mitochondrial fission protein Drp1 contribute to mitotic adaption. Our results reveal crosstalk between the apoptosis and adaptation pathways during mitotic arrest.

Indexed as

ApoptosisMitosisAdaptation, PhysiologicalAntineoplastic AgentsEpithelial CellsGene Expression ProfilingHeLa CellsHumansPaclitaxelRNA, Small InterferingAntineoplastic AgentsPaclitaxelRNA, Small Interferingapoptosismitochondriamitosismitotic slippagethe spindle checkpoint

Identifiers

PMID25024437
PMCPMC4195789
OpenAlexW2091527261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.